Changes in Bacterial Gut Composition in Parkinson’s Disease and Their Metabolic Contribution to Disease Development: A Gut Community Reconstruction Approach

Johanna Forero-Rodríguez,Johannes Zimmermann,Jan Taubenheim,Natalia Arias-Rodríguez,Juan David Caicedo-Narvaez,Lena Best,Cindy V. Mendieta,Julieth López-Castiblanco,Laura Alejandra Gómez-Muñoz,Janneth Gonzalez-Santos,Humberto Arboleda,William Fernandez,Christoph Kaleta,Andrés Pinzón
DOI: https://doi.org/10.3390/microorganisms12020325
IF: 4.5
2024-02-04
Microorganisms
Abstract:Parkinson’s disease (PD) is a chronic and progressive neurodegenerative disease with the major symptoms comprising loss of movement coordination (motor dysfunction) and non-motor dysfunction, including gastrointestinal symptoms. Alterations in the gut microbiota composition have been reported in PD patients vs. controls. However, it is still unclear how these compositional changes contribute to disease etiology and progression. Furthermore, most of the available studies have focused on European, Asian, and North American cohorts, but the microbiomes of PD patients in Latin America have not been characterized. To address this problem, we obtained fecal samples from Colombian participants (n = 25 controls, n = 25 PD idiopathic cases) to characterize the taxonomical community changes during disease via 16S rRNA gene sequencing. An analysis of differential composition, diversity, and personalized computational modeling was carried out, given the fecal bacterial composition and diet of each participant. We found three metabolites that differed in dietary habits between PD patients and controls: carbohydrates, trans fatty acids, and potassium. We identified six genera that changed significantly in their relative abundance between PD patients and controls, belonging to the families Lachnospiraceae, Lactobacillaceae, Verrucomicrobioaceae, Peptostreptococcaceae, and Streptococcaceae. Furthermore, personalized metabolic modeling of the gut microbiome revealed changes in the predicted production of seven metabolites (Indole, tryptophan, fructose, phenylacetic acid, myristic acid, 3-Methyl-2-oxovaleric acid, and N-Acetylneuraminic acid). These metabolites are associated with the metabolism of aromatic amino acids and their consumption in the diet. Therefore, this research suggests that each individual’s diet and intestinal composition could affect host metabolism. Furthermore, these findings open the door to the study of microbiome–host interactions and allow us to contribute to personalized medicine.
microbiology
What problem does this paper attempt to address?
The problem that this paper attempts to solve is the differences in gut microbiota composition between Parkinson’s Disease (PD) patients and healthy control groups, and how these differences affect the development of the disease through metabolic pathways. Specifically, the researchers focused on the following aspects: 1. **Alterations in gut microbiota composition**: Using 16S rRNA gene sequencing technology, the researchers analyzed fecal samples from 25 PD patients and 25 healthy controls in Colombia to determine the differences in gut microbiota composition between PD patients and healthy individuals. 2. **The influence of dietary habits**: The study also explored the impact of dietary habits on gut microbiota, particularly the differences in the intakes of carbohydrates, trans - fatty acids, and potassium between PD patients and healthy control groups. 3. **Changes in metabolites**: Through personalized computational models, the researchers simulated the metabolic activities of gut microbial communities and found predicted changes in the production of seven metabolites (indole, tryptophan, fructose, phenylacetic acid, myristic acid, 3 - methyl - 2 - oxovaleric acid, and N - acetylneuraminic acid) between the two groups. 4. **Cross - cultural research**: Most previous studies on gut microbiota in PD patients have focused on cohorts in Europe, Asia, and North America, while data on Latin American populations are relatively scarce. Therefore, this study fills this gap and provides important information for understanding the characteristics of gut microbiota in PD patients from different cultural backgrounds. In summary, this paper aims to explore the role of gut microbiota in the pathogenesis of PD by analyzing the gut microbiota composition and its metabolic contributions in Colombian PD patients and healthy control groups, and to provide potential therapeutic targets for personalized medicine.